Prompt Record a short investor pitch video that highlights why the identified alternative buyer should be interested in buying the organization in the case scenario. Your video should i

Johnathon Davis

4-1 Report: Potential Alternative Buyers/Competitor Research

MBA 699

Professor Shindell

September 18, 2022

4-1 Report: Potential Alternative Buyers/Competitor Research

Introduction

As a business development manager for a life sciences firm, to find higher success in new cancer treatment medications. The report focuses on identifying and studying the top three firms in the market and industry. The data is summarized in a report to the VP because the list of organizations is considered for the alternative purchaser. Firstly, the North American Industry Classification system code is discussed to find purchasers in the segment. Secondly, three competitors are considered by focusing on the NAICS code. Lastly, the CAGR, market share, primary services and products and strategic vision of Gilead Science Inc, Eli Lilly and Company, and Novartis Pharmaceuticals Corporation are explained effectively.

North American Industry Classification System (NAICS) Code

The NAICS code for the life science company is 325412, the code for the pharmaceutical preparation business. The code is for the industry of manufacturing organizations that create in-vivo pharmaceutical and diagnostic preparations that can be used both externally and internally. NAICS code can aid in finding essential data related to organizations in a similar industry (census.gov, 2022). The code will be necessary for finding effective purchasers as it delivers data about top organizations in the industry. It would be attentive to manufacturing can treatment medicines. The NAICS code provides an overview of data related to the organization that aids in deciding which organization will be the top fit for the organization.

Top Competitors

The top three firms in the pharmaceutical preparation manufacturing industry with a NAICS code of 325412 are Gilead Science Inc, Eli Lilly and Company, and Novartis Pharmaceuticals Corporation (Lopes et al., 2013). These organizations are the major competitors for the life science firm and might be alternative purchasers for the organization. The standards utilized to select these three organizations comprise organizations' income and sales volume. Besides, the revenue and sales volume are essential to focus on the consumer pool of the organization and if they have a good effect in the market to confirm the cancer treatment medicines that can reach various persons possibly. This standard affects the life science firm if the acquiring organization does not possess the need to vend the treatment, and obtaining organization might not focus on purchasing the firm. So, it also confirms that a life science organization intends to make the medicine available to all that require it is completed if the organization has a distinct possessor.

Besides, the maturity and size of the organization are focused on selecting three firms. The size of a firm is essential as a larger organization will aid in decreasing competition and improving purchasing strength (Kessel, 2014). The maturity of an organization is crucial in confirming that the organization can reduce issues that may cause the organization to close. The maturity and size of the acquisition organization are necessary for a life science firm as they will confirm that the organization will keep running its operations. Resources of the organization are the third criterion utilized to make decisions related to the top three competitors of life science firms. The standard is crucial as it confirms that the firm inclines to need other organizations and also has the capital to purchase them. So, it is essential for a life science firm as it confirms that the receiving firm has the funding to fulfill the acquisition.

Furthermore, the criteria focused on selecting the top three organizations and were not utilized to comprise the culture and location of the company. The location is a crucial aspect to be focused on as it influences the lives of workers and their family members. If an organization is in another zone and might decide to move the organization, it will make the workers locate again. It was not utilized as a criterion as some jobs can be completed remotely, and this movement might not influence various workers (Petrova, 2014). The organizational culture is another criterion to be focused on as an organization's culture is an essential aspect during merger and acquisition that determines the working of employees efficiently.

Company Information

Novartis Pharmaceuticals Company is an international pharmaceutical firm based in Switzerland and USA. It is among the major pharmaceutical firms worldwide and makes numerous drugs. The organization was founded in 1996 once the divisions of Sandoz and Ciba-Geigy merged. Its net income was 51 billion dollars in 2021, which was high than the net income of 2020 (Novartis, 2022). The organization has about 7000 workers and delivers approximately 107 medicines in the United States. Moreover, the company focuses on improving healthcare problems through innovation and technology by designing breakthrough treatments and making them approachable to various persons as latent.

Besides, Eli Lilly and Corporation is a pharmaceutical organization in the USA and is present in the USA and other eighteen states. Eli Lilly founded the organization in 1876, and the firm is focused on creating quality medicine (Lilly, 2022). The critical values of the company comprise respect, excellence and integrity for persons that focus on inclusion, diversity, and creativity. The organization also focuses on bringing innovation in innovative ideas to bring improvement in medicine’s quality. So the company also has about 36,000 employees all over the world.

Furthermore, Gilead Science Incorporation is a pharmaceutical organization in the USA that focuses on producing and researching anti-viral treatments. The firm's main aim is to develop medicine for persons with life-endangered illnesses utilizing transformative and bold technology and science (Gilead, 2022). Therefore, the firm focuses on developing and researching medicine for unfulfilled medical requirements. It also considers cancer studies and other illnesses that need to be fulfilled.

Conclusion

It is concluded that competitor analysis helped examine organizations' performance in the life sciences industry while focusing on medicines and pharmaceuticals. Team members of firms agree with the approaches and conduct preliminary research that might not aid in acquisition evaluation and recognition of alternative purchasers in present purchasers back out.

References

census.gov. (2022). Introduction to NAICS. Retrieved from census.gov: https://www.census.gov/naics/

Gilead. (2022). Decades of Achievements: Celebrating 35 Years. Retrieved from Gilead: https://www.gilead.com/

Gilead. (2022). Gilead UK and Ireland. Retrieved from Gilead: https://www.gilead.co.uk/

Lilly. (2022). Leading with Purpose. Retrieved from Lilly: https://www.lilly.com/

Novartis. (2022). Novartis Pakistan. Retrieved from Novartis: https://www.novartis.com/pk-en/

Lopes, G. D. L., De Souza, J. A., & Barrios, C. (2013). Access to cancer medications in low-and middle-income countries.  Nature Reviews Clinical Oncology,  10(6), 314-322.

Petrova, E. (2014). Innovation in the pharmaceutical industry: The process of drug discovery and development. Innovation and marketing in the pharmaceutical industry (pp. 19–81). Springer, New York, NY.

Kessel, M. (2014). Restoring the pharmaceutical industry's reputation.  Nature Biotechnology,  32(10), 983–990.

Johnathon Blake Davis

2-1 Milestone One: Guiding Coalition Recommendations

MBA 699

Professor Shindell

September 2, 2022

Recommendation

Leadership and management skills are crucial to guide the coalition effectively. Decision-making ability and credibility to participate in teamwork are crucial to leading positive change and getting expected outcomes. Following members of the organization are recommended to participate in guiding the coalition process;

1. Flora Berggren, the vice president of worldwide sales, manages 150 sales representatives under her. She has been with the organization for ten years; thus, she understands organizational values and goals. Berggren influences the sales operations of the organization. She manages two people under her as a sales executive and sales representative. During her presence with the organization, she always achieved her targets regarding worldwide sales. She is a committed person; thus, her participation in guiding the coalition would be helpful. As the sales president, she knows global market trends and can guide the team to make productive decisions.

2. Elaine Hartwick, the acting director, manages 18 senior managers under her. She has been with the organization for ten years and is known because of her visionary and leadership expertise. According to the data, Elanie is the best cooperative manager in adapting to new situations. Throughout her presence with the organization, Elanie always motivates others and helps them to recognize their strengths. Her participation in the guiding coalition team would be helpful for team members to stay motivated and active. Her market management skills would be helpful in placing the product at the right place, at the right time.

3. Omar Mattsson, the manufacturing director at the firm, manages 580 hourly workers in 12 plants. He has proved a strong and effective director who helps the organization to expand towards the Middle East. He manages 12 manufacturing plants and works competently with the organization to achieve goals. He has been working with the organization for three years and is pleased with the integration within the organization. His participation in the guiding coalition team would help us to understand the global perception of the product, and it would be helpful to predict the future of the product launched.

4. Leslie, the sales representative, is an individual contributor to the organization. He has been serving the organization for fourteen years. According to his records in the organization, Leslie always meets her sales targets and exceeds sales quotas every quarter. His contributions to the guiding coalition would help to understand the effective strategy required to sell the new product in the right market. He would utilize his experience to make sales effective and help to achieve expected outcomes.

Team Building Strategies

A well-functioning team is crucial to initiate change in the previous operational performance of the organization. The organization’s board of directors decided to sell the new product, and for this, team building is the first step which would help to make the process successful. Following are some strategies for developing a functioning team;

1. Promote a Respectful Environment

One of the most focused strategies is to promote a respectful environment for team members. A respectful environment in which every team member feels valued and shows respect to each other. Even during stressful times, maintain a cooperative and respectful environment to cope with negative situations.

2. Communicate

Communication is key to establishing a smooth and comfortable relationship with team members. There should be professional and ethical communication standards to improve the interaction between team members. Communicating is also important to exchange ideas and opinions within a team. Communication is also a dedication to transparency and improvement in interpersonal relationships.

3. Trust in Each Member's Efficiency

It is important to show everyone their ideas are worth considering to prevent team conflicts. Saw value in each other and motivated each other to utilize their strengths. To build a functioning team, accepting and respecting each other's opinions is important. Instead of criticizing individual opinions and perspectives, team members should share positive feedback.

4. Acknowledgement and Feedback

A team leader should show a response toward the performance of team members. Regular feedback improves the performance of individuals and motivates them to do more. Acknowledgement of small achievements motivates team members to work hard and achieve expected outcomes. To lead a positive change, it is crucial to interact with team members and understand their concerns properly.

5. Listen to Each other

To build a strong team, it is important to instill the skill that each member has different beliefs, ideas and perspectives. Thus, listening to others could improve our understanding and knowledge of the subject. Listen to others and understand what they think about the problem. Listening to each other also improves team connectivity (VANTAGE, 2022).

Along with these five team-building strategies to build a sense of urgency among team members, we will guide them about the need of the organization to embrace change. Although the organization has been doing good for years, change is still mandatory. And a successful change can only happen when everyone contributes equally and show their commitment to the organizational change. Understanding the need for change is also important to be ready for the change and participate in its process. Understanding and accepting each team member are crucial to embracing a long-term positive change. If any of the team members resisted, it would become difficult to achieve the expected outcomes.

All these strategies and activities would help to build trust because, in this way, each member will feel valued and respected. The organization’s management will try to engage each member in the guiding coalition by satisfying their concerns and preferences. These activities will enhance their trust in the organization. Trust is a binding force while working in a team; thus, building it by different means is crucial. Strategies enlisted to build a functioning team also help to improve interpersonal relationships between team members. Trust in each other would make them respect each other's opinions and perspectives to embrace the required change. These strategies would help achieve expected outcomes by the launch of the new product.

Reference

VANTAGE, C. (2022). The Right Steps to Develop an Effective Team.

5-1 Milestone Three: Alternative Buyer Research Report and Acquisition Road Map

MBA 699

Professor Shindell

September 24, 2022

5-1 Milestone Three: Alternative Buyer Research Report and Acquisition Road Map

The potential buyer selected for the organization is Vertex Pharmaceuticals. It is an American biopharmaceutical company based in Boston, Massachusetts. The company is known for its focus on innovation in research, manufacturing and distribution of medicines for severe illnesses. Vertex Pharmaceuticals was one of the first biofilm-producing medicines for life-threatening diseases and serious illnesses. Its customer's rate Vertex Pharmaceuticals up to 4.2 from 5 based on the services offered to customers. According to the organization's mission, Vertex Pharmaceuticals invests in scientific innovation to manufacture transformative medicine to deal with life-threatening and severe illnesses. Organizational values at Vertex Pharmaceuticals drive the operations and functions of the team. In this paper, we will discuss the current situation of Vertex Pharmaceuticals (Bakiny, 2022).

Current Market of Vertex Pharmaceuticals

The organization is operating in the pharmaceutical market in the United States. It holds a monopoly in the CF market. The company looks forward to working outside the CF market and diversifying its services through different locations. Based on the quality of research and manufacturing at Vertex Pharmaceuticals, it is expected that the organization will also gain enormous success in other regions. The uniqueness and differentiation that the organization has maintained would help it to compete across different locations and diversify its position in the international market (Bakiny, 2022).

Vertex Pharmaceuticals is the only firm manufacturing medicines to deal with healthcare complications. Some products manufactured by the company include TRIKAFTA/KAFTRIO, KALYDECO, SYMDEKO/SYMKEVI and ORKAMBI. These four medicines manufactured by Vertex are used to treat CF in the regions of Australia, North Africa and Europe. The company is also manufacturing other medicines to deal with chronic situations. Vertex Pharmaceuticals manufactures medicines by considering patient needs, and there is no compromise when it comes to a commitment to patients (Bakiny, 2022). Patients are central forces, and everything is for them what we do. Decisions from planning to manufacturing focus on patient need and ensure that organizational decisions should not impact customers.

All the patients suffering from severe life-threatening diseases are customers of Vertex Pharmaceuticals. The company is serving the medical needs of patients and using technology to manufacture transformative medicines for patients. The company invests in research, innovation and advancement to transform traditional medicine methods. All the company's decisions, programs and initiatives focus on patients and serving their needs directly or indirectly (VERTEX, 2009).

Vertex Pharmaceuticals is competing in the pharmaceuticals and biotherapeutics industry. It is serving the healthcare sector and innovating means of medicine. Some competitors of Vertex Pharmaceuticals include Biogen Mayokardia and Bellicum pharmaceuticals (Comparably, 2020). Vertex Pharmaceuticals is leading the market because of the innovation it drives in the healthcare sector and its distinct focus on health and medicine.

Financial Situations

According to the financial performance of the company in 2021, the product revenue of the company has increased compared to the previous year. Along with the overall success throughout the business, 22% revenue growth is recorded. According to the Chief Executive Officer and President of Vertex Pharmaceuticals, "we expanded our leadership in cystic fibrosis– treating more patients than ever before and advancing our next-in-class triple regimen into pivotal studies. In addition, our pipeline beyond CF accelerated and delivered important clinical data in new disease areas" (VERTEX, 2022). She further states that moving in 2022, we have numerous other programs in mind that would help improve revenue growth even higher. We are motivated to serve many more patients, driving revenue growth and earnings in 2022 and years ahead (VERTEX, 2022). Financial highlights of the company during the second quarter of 2022 are as follows;

(VERTEX, 2022)

According to the chart above, the product revenue increased about 22%, $7.57 billion, compared to the previous year. The chart also shows that during 2022 cash flow and market securities increased by $9.3 billion compared to the previous year in 2021. The company's financial growth is dedicated to launching two products in the market, including KAFTRIO and TRIKAFTA. These two products have increased the operating income of Vertex and positively impacted the company's financial performance (VERTEX, 2022).

Recent Developments

Analysis of the recent developments in the company shows that the whole emphasis of Vertex Pharmaceuticals is on introducing new medicines to deal with chronic illnesses. Vertex Pharmaceuticals currently collaborates with Verve Therapeutics to discover and develop a gene editing program to address liver disease. According to the Chief Executive Officer at Vertex Pharmaceuticals, “This partnership with Vertex enables an important step forward for Verve as we build out our leading gene editing capabilities and pipeline of in vivo gene editing medicines to address serious diseases” (VERTEX, 2022). This initiative shows growing investments and efforts of the organization towards innovation and transformation of the healthcare sector.

Vertex Pharmaceuticals are also investing in improving technological advancement and embracing innovation in the workplace. The organization's purpose is to address chronic illnesses and improve the outlook of treatments for patients. The entire focus on innovation and advancement would improve patient and community care outcomes.

Buyer Rationale

Vertex Pharmaceuticals is the best option for a life sciences organization because the mission and purpose coincide. Vertex Pharmaceuticals focuses on cell, biology, and molecular level solutions, which is what the life sciences organization is doing; thus, collectively, both organizations can make a difference. Collaboration of Vertex Pharmaceuticals with life sciences organizations will help to manufacture products to treat chronic illnesses and would help to improve overall outcomes of healthcare for patients.

Acquisition Road Map

The organization for the acquisition is selected, and the next process is to negotiate business terms and conditions with each other. Both companies, Vertex Pharmaceuticals and the life sciences organization, will organize a meeting to discuss the agenda of the acquisition and share their expectations from each other. After the agenda setting, another meeting would be called to share common goals achieved through this acquisition. The roles and responsibilities of both companies will be communicated to eliminate complications later. Vertex Pharmaceuticals will explain its focus on research to drive innovation and how the organization could help it research and develop required changes in the contract. In the coming year, the manufacturing of new life-saving drugs will be discussed, along with changing market trends and patient needs. There would be different times and meetings to discuss all these things, and the road map would be implemented within two months to pursue decided goals in the coming year. Internal stakeholders from both organizations will participate in meetings and achieve acquisition goals. The roles and responsibilities of each stakeholder would be highlighted for them.

References

Bakiny, J. (2022, June 3). 2 Green Flags for Vertex Pharmaceuticals' Future. The Motley Fool. Retrieved September 25, 2022, from https://www.fool.com/investing/2022/06/03/2-green-flags-for-vertex-pharmaceuticals-future/

Comparably. (2020). Vertex Pharmaceuticals Competitors. Comparably. Retrieved September 25, 2022, from https://www.comparably.com/companies/vertex-pharmaceuticals/competitors

VERTEX. (2009, July 2). Home. YouTube. Retrieved September 25, 2022, from https://www.vrtx.com/patients/

VERTEX. (2022, January 26). Vertex Reports Second Quarter 2022 Financial Results. Vertex Pharmaceuticals. Retrieved September 25, 2022, from https://news.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2022-financial-results

VERTEX. (2022, July 20). Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom. Newsroom | Vertex Pharmaceuticals Newsroom. Retrieved September 25, 2022, from https://news.vrtx.com/news-releases/news-release-details/vertex-and-verve-therapeutics-establish-collaboration-discover-0

Johnathon Davis

3-1 Milestone Two: Employee Attrition Analysis Report

MBA 699

Professor Shindell

September 11, 2022

3-1 Milestone Two